Patient Characteristics Influence the Choice of Biological Drug in RA, and will make non-TNFi Biologics appear more Harmful than TNFi Biologics
Ann Rheum Dis 2018; 77:650–57 DOI: 10.1136/annrheumdis-2017-212395
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis 2018; 77:650–57 DOI: 10.1136/annrheumdis-2017-212395
RMD Open. 2018 May 8;4(1):e000662. DOI: 10.1136/rmdopen-2018-000662
Drug Saf 2018 Apr; 41(4):357–61 DOI: 10.1007/s40264-017-0622-2
Pharmacoeconomics 2018 Sep; 36(9): 1063–72
Arthritis Res Ther 2018; 20(1):60 doi: 10.1186/s13075-018-1539-6
Rheumatol Ther 2018 Jun; 5(1):283–91
Please click the links below to go to the CSF review of each paper.
Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. DOI: 10.1093/rheumatology/kex443
J Rheumatol 2018 Apr; 45(4):456-464
Rheumatology (Oxford) 2017 Dec 1;56(12):2179-2189 doi: 10.1093/rheumatology/kex319